Table 3 Findings of the work-up of cervical cancers at advanced (group B) versus localized (group A) stage
From: Diagnosis of advanced cervical cancer, missed opportunities?
Group A N = 25 | Group B N = 71 | p-value | |
|---|---|---|---|
Normal vaginal examination | 9/21 (42.86%) | 1/56 (1.79%) | < 0.001 |
PET scan findings | < 0.001 | ||
Local hypermetabolism | 14/15 (93.33%) | 14/52 (26.92%) | |
Hypermetabolism extended in pelvis | 1/15 (6.67%) | 31/52 (59.62%) | |
Hypermetabolism beyond pelvis | 0/15 (0%) | 7/52 (13.46%) | |
MRI findings | < 0.001 | ||
Cervical lesion < 4 cm | 13/21 (61.90%) | 3/63 (4.76%) | |
Cervical lesion > 4 cm | 0/21 (0%) | 7/63 (11.11%) | |
Extension to parametrium and/or pelvic lymph nodes | 3/21 (14.29%) | 37/63 (58.73%) | |
Extension to parametrium and pelvic, iliac and para-aortic lymph nodes | 0/21 (0%) | 8/63 (12.70%) | |
Extension to bladder. Ureters or rectum | 0/21 (0%) | 8/63 (12.70%) | |
No MRI lesions | 5/21 (23.81%) | 0/63 (0%) | |
Distant metastases | 0/22 (0%) | 11/51 (21.57%) | 0.013 |
Pathology | |||
Squamous cell carcinoma | 14/25 (56%) | 62/71 (87.32%) | 0.001 |
Adenocarcinoma | 11/25 (44%) | 9/71 (12.68%) | 0.001 |